These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 31124388)

  • 21. Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus.
    Nyholm B; Brock B; Ørskov L; Schmitz O
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1641-52. PubMed ID: 11772274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequence specificity of amylin-insulin interaction: a fragment-based insulin fibrillation inhibition study.
    Ratha BN; Kar RK; Kalita S; Kalita S; Raha S; Singha A; Garai K; Mandal B; Bhunia A
    Biochim Biophys Acta Proteins Proteom; 2019 Apr; 1867(4):405-415. PubMed ID: 30659960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microcanonical insights into the physicochemical stability of the coformulation of insulin with amylin analogues.
    Frigori RB; Rodrigues F
    J Mol Model; 2021 Jan; 27(2):28. PubMed ID: 33411018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of amylin gene transcription by LIM domain homeobox gene isl-1.
    Wang M; Drucker DJ
    Mol Endocrinol; 1996 Mar; 10(3):243-51. PubMed ID: 8833653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
    Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
    Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete characterization of the mutation landscape reveals the effect on amylin stability and amyloidogenicity.
    Smaoui MR; Waldispühl J
    Proteins; 2015 Jun; 83(6):1014-26. PubMed ID: 25809921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
    Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
    Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pramlintide (Amylin).
    Barlocco D
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1575-81. PubMed ID: 11763160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of amylin in glucose homeostasis and its perspective use in diabetes management].
    Otto-Buczkowska E; Mazur-Dworzecka U; Dworzecki T
    Przegl Lek; 2008; 65(3):135-9. PubMed ID: 18624122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and characterization of PEGylated amylin.
    Guerreiro LH; Guterres MF; Melo-Ferreira B; Erthal LC; Rosa Mda S; Lourenço D; Tinoco P; Lima LM
    AAPS PharmSciTech; 2013 Sep; 14(3):1083-97. PubMed ID: 23818080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nephrectomy decreases amylin and pramlintide clearance in rats.
    Vine W; Smith P; LaChappell R; Blase E; Lumpkin R; Young A
    Horm Metab Res; 1998 Aug; 30(8):514-7. PubMed ID: 9761382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
    Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
    Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
    Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
    Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Amylin in Type 1 and Type 2 Diabetes.
    Hieronymus L; Griffin S
    Diabetes Educ; 2015 Dec; 41(1 Suppl):47S-56S. PubMed ID: 26424675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterotropic Modulation of Amylin Fibrillation by Small Molecules: Implications for Formulative Designs.
    Sinézia C; Lima LMTR
    Protein J; 2020 Feb; 39(1):10-20. PubMed ID: 31808036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.
    Xu P; Ye X; Zhang Y; Yuan Q; Liu M; Wu Q; Ren G; Li D
    J Diabetes Complications; 2015; 29(1):5-12. PubMed ID: 25456819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plain and mono-pegylated recombinant human insulin exhibit similar stress-induced aggregation profiles.
    Torosantucci R; Kukrer B; Mero A; Van Winsen M; Tantipolphan R; Jiskoot W
    J Pharm Sci; 2011 Jul; 100(7):2574-85. PubMed ID: 21344414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes.
    Gallagher EJ; Zelenko Z; Tobin-Hess A; Werner U; Tennagels N; LeRoith D
    Diabetologia; 2016 Sep; 59(9):2018-25. PubMed ID: 27241182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.